Bank of America Securities Remains a Buy on BioNTech SE (BNTX)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioNTech SE today and set a price target of $134.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ahmad covers the Healthcare sector, focusing on stocks such as Neurocrine, Ascendis Pharma, and Rhythm Pharmaceuticals. According to TipRanks, Ahmad has an average return of 2.6% and a 52.93% success rate on recommended stocks.
In addition to Bank of America Securities, BioNTech SE also received a Buy from Morgan Stanley’s Terence Flynn in a report issued yesterday. However, on the same day, TipRanks – xAI reiterated a Hold rating on BioNTech SE (NASDAQ: BNTX).
Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 billion and a GAAP net loss of $28.7 million. In comparison, last year the company earned a revenue of $1.24 billion and had a net profit of $198.1 million
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.
Read More on BNTX:
Disclaimer & DisclosureReport an Issue
- BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX
- Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch
- Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig
- Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
- Moderna Stock (MRNA) Hits a New 52-Week High — Can the Rally Last Through 2026?
